In this episode, Gideon Korrell breaks down the Federal Circuit’s ruling in Janssen v. Teva, where the court upheld Janssen’s patent on paliperidone palmitate’s unique dosing regimen. He explains why the case matters for pharmaceutical patents, Hatch-Waxman disputes, and the limits of obviousness in drug development.

Gideon Korrell Talks About Paliperidone Palmitate Patent Ruling

Gideon Korrell, a seasoned legal professional with 15+ years of experience, seamlessly bridges engineering and law. Transitioning from nuclear power and defense engineering to law, Gideon Korrell has excelled as a trusted advisor in global firms and as an in-house counsel. Committed to environmental sustainability, Gideon Korrell forges partnerships to decarbonize the global economy. His expertise in negotiating complex agreements, integrating legal and technological perspectives, and upholding ethical business practices positions him as a catalyst for success in today's dynamic global arena.

New tracks tagged #PharmaPatents